To provide the information your oncologist is not telling you or doesn't have the time to!
A new article published in the NEJM showing impressive efficacy in NSCLC, here’s the summary below. The landscape of non-small cell lung cancer (NSCLC) treatment continues to evolve, particularly for patients with EGFR mutations. Historically, EGFR tyrosine kinase inhibitors (TKIs) like osimertinib have been the first line of defense, providing improved progression-free survival for patients. …
The journey of treating patients with advanced cancer, like metastatic gastric cancer, often brings clinicians face to face with difficult conversations surrounding prognosis, treatment goals, and emotional dissonance. As we make strides in cancer therapies, the complexity of managing patient expectations, cognitive awareness, and emotional resilience becomes more apparent, both for patients and clinicians. A …
Hope for Advanced Bladder Cancer Bladder cancer is often like an unwelcome party crasher, popping up when least expected and causing considerable distress. Yet, in the realm of oncology, we are constantly seeking new ways to send such unwelcome guests packing. Today, I am thrilled to share some exciting news about a promising new approach …
Immunotherapy has made significant strides in cancer treatment, but microsatellite stable (MSS) metastatic colorectal cancer (mCRC) has long posed a challenge due to its resistance to immune-based therapies. However, promising results from a recent phase 2/3 trial have shown that the individualized neoantigen-directed immunotherapy, GRANITE, may change the outlook for patients with MSS mCRC. This innovative therapy, combined …
The world recently lost NBA legend Dikembe Mutombo to brain cancer, while former President Jimmy Carter continues to defy expectations. Despite being diagnosed with metastatic melanoma, including brain and liver metastasis he has just celebrated his 100th birthday. These two public figures have brought significant attention to CNS (Central Nervous System) malignancies, sparking curiosity about the different types of brain tumors, how …
On October 10, 2024, the FDA approved a new and promising treatment for patients with advanced breast cancer: inavolisib (Itovebi), in combination with palbociclib and fulvestrant. This new approval offers fresh hope for patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, and HER2-negative breast cancer, especially those whose disease has progressed after endocrine therapy. The approval also includes the FoundationOne Liquid CDx assay, a diagnostic test used to …
Small-cell lung cancer (SCLC) is a notoriously aggressive form of lung cancer, making up about 15% of all lung cancer cases. While treatments have made strides in extensive-stage SCLC, limited-stage SCLC has seen few advancements in decades—until now. A new clinical trial published in the New England Journal of Medicine has revealed promising results with the use …
A Promising New Treatment for Metastatic Breast Cancer: Exploring Bria-IMT™ and Its Impact When battling metastatic breast cancer, finding effective treatment options can feel like an uphill battle, especially when cancer has spread to other areas, like the brain. But new hope is on the horizon. A groundbreaking therapy called Bria-IMT™ is showing promising results in clinical …
Breast Cancer Treatment October is Breast Cancer Awareness Month, a time dedicated to spreading knowledge, supporting research, and empowering patients and healthcare providers alike. Throughout the month, we’ll explore various critical aspects of breast cancer care. In this post, we focus on the current role of targeted therapies in treatment and encourage both patients and …
Bladder Cancer Bladder cancer is one of the most common cancers in the world. About 81,000 new cases are diagnosed annually in the U.S. alone. While it’s more common in men, it affects thousands of women as well. Most bladder cancers are urothelial carcinomas. If caught early, they can often be treated successfully. However, for patients with muscle-invasive …